AstraZeneca plc vs Smith & Nephew plc vs Indivior PLC: Which Healthcare Stock Should You Buy?

If you could only choose one healthcare company to add to your portfolio, should it be AstraZeneca plc (LON: AZN) Smith & Nephew plc (LON: SN) or Indivior PLC (LON: INDV)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When it comes to healthcare stocks, there is a huge difference in earnings stability and consistency between pharmaceutical companies and healthcare equipment/devices providers. In the case of the former, earnings are likely to be far more volatile, as they depend upon new drugs constantly being developed to replace those going off patent, while for the latter there is much more consistency due to relatively stable demand for products and a slower changing industry.

Track Records

This difference is evidenced by the bottom lines of pharmaceutical company, AstraZeneca (LSE: AZN) (NYSE: AZN.US), and healthcare equipment/devices provider, Smith & Nephew (LSE: SN) (NYSE: SNN.US). For example, during the last five years AstraZeneca has seen its earnings decline by an incredible 33%, as it has been unable to replace a number of key, blockbuster drugs that have lost their patent protection. Meanwhile, Smith & Nephew has delivered earnings growth in four of the last five years, with its net profit being 26% higher in 2014 than it was in 2009.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Looking Ahead

Of course, AstraZeneca is due to return to growth in 2017 and, as a result of an aggressive acquisition programme, has a pipeline that looks set to offer a purple patch over the medium term. However, in the next two years it is expected to post a fall in earnings of 6%, as further sales falls are anticipated. This contrasts markedly with Smith & Nephew, which is expected to see its bottom line flat line this year, before growing by an impressive 13% next year.

However, AstraZeneca’s near term potential seems to be much more appealing than pharmaceutical peer, Indivior (LSE: INDV). Sales for its main drug, suboxone, are falling due to a loss of patent protection and the company is expected to see its bottom line fall by 59% this year and by a further 21% next year. Certainly, it has the potential to deliver other drugs and has an impressive pipeline, but investor sentiment could shift downwards unless it makes progress in this regard during the next couple of years.

Valuation

The main downside of buying Smith & Nephew is its valuation. It currently trades on a price to earnings (P/E) ratio of 21 which, despite its greater stability and consistency, lacks appeal when you consider that AstraZeneca has a P/E ratio of 17.2. And, with Indivior’s P/E ratio set to rise to 16 next year, it may offer better value than AstraZeneca but has a less diverse pipeline and higher risk future.

Therefore, AstraZeneca seems to offer the best mix of risk and reward of the three companies, with it occupying a middle ground in terms of having long term growth potential via its upbeat pipeline, but also offering diversity so as to reduce the risk of further challenges moving forward.

More on Investing Articles

Portrait of construction engineers working on building site together
Investing Articles

Is this FTSE 100 stock the best housebuilder to invest in?

One FTSE 100 housebuilding stock has outperformed all of its industry peers by a big margin this year. Should I…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

2 cheap dividend growth stocks I’d buy as the economy sinks

I'm searching for the best bargains to buy following recent market volatility. Here are two top dividend growth stocks I…

Read more »

estate agent welcoming a couple to house viewing
Investing Articles

Here’s 1 FTSE stock primed to benefit from the current housing market!

With the current housing market as it is, Jabran Khan explores a related FTSE stock that could provide stable and…

Read more »

Portrait of construction engineers working on building site together
Investing Articles

Here’s why this AIM-listed stock could be one of the best shares to buy!

This Fool is looking for the best shares to buy. Despite macroeconomic issues, this stock could be a great long-term…

Read more »

Elderly father and adult son work in the garden
Investing Articles

This penny stock could be set to soar! Should I buy shares?

This Fool looks closely at a penny stock operating in an exciting growth market that could see its shares rise…

Read more »

Illustration of bull and bear
Investing Articles

The next stock market recovery looks imminent

As the stock market bear gives way to the bull, some stocks are already turning up and I'm ready to…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

2 dividend shares to protect me from soaring inflation

Dividend shares can be an excellent way to keep up with inflation. Our writer explores several options to protect his…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Is it time to buy Unilever stock?

Unilever stock has underperformed in the last five years. But with its portfolio of powerful brands, should I buy now…

Read more »